Consolidated Financial Result Briefing
for the Nine Months ended December 31, 2022

CYBERDYNE, Inc.
February 14, 2023

Consolidated financial results (IFRS)
Year-on-year comparison for the nine months ended December 31, 2022

Revenue: 2,374M (+76% YoY)
Operating profit: ¥-749M (-93M YoY)
Final profit: ¥68M (Improved by 659M YoY)
(Unit: Millions of yen)

FY2021
Q1-Q3

Revenue(Gross profit)

FY2022
Q1-Q3+/-+/-%

1,347

2,374+1,027 *1+76.3％ *1(984)(1,482)(+497)(+50.5%)*２

Operating profit-656-749

Profit before tax-554

112

Rental +190M (HAL for overseas)
Sales+54M (Increase of sales of product for research)
Service +782M (Treatment service by RISE Group in USA)

*２ Increase in SG&A (631M) (YoY)-93

ー+666ー*３ *４*1 Increase in revenue（1,027M）（YoY）

SG&A expenses of consolidated subsidiary acquired
through M&A +694M*３ Exchange gain 55M (in finance income)*４ Gains related to investment securities 851M
（Net）

Profit attributable toowner of the parent-590

68+659ー

Finance income (gain on valuation) +588M
Gains related to CEJ +263MRef) revenue related to investment securities in thefirst half of the previous fiscal year 86M (net)
3

Consolidated financial results (IFRS)
Performance trends【Q3 Results】Revenue +5% QoQ, +59% YoYConsolidated statementof profit or loss

Revenue

FY2021Q3Q1Q2FY2022Q3

Q1-Q3

Quarter on Quarter+/-+/-%(Unit : Millions of yen)

Year on Year+/-+/-%

521

751

791

831

2,374+41+5.1%+310+59.4%

156261292

339892+47+16.1%+183+117.1%

365

490

499

492

1,482

-6-1.3%+127+34.8%

R&D expenses

173

151

182

161

494

-21-11.3%-12-6.7%

Other SG&A

401

568

594

652

1,814

+58+9.8%+250+62.4%

Other income/expenses

3451

121377+1+6.0%-21-61.3%

Operating profit

-175

-178

-264

-307

-749

-43

-

-133

-

Finance income/expense

3541

134

10685

-123

-92.3%+8+289.6%

Other89132

36

176

-96

-72.9%+28+371.3%

Profit before tax

-164

372

1-261

112-263--97-

Profit attributable toowner of the parent-162

241

27-20068-226--37-

Cost of sales
Gross profit

gain on valuation difference of investments securities +109M, translation of foreign operations -99M

5

Consolidated financial results (IFRS)
by types of transaction
Increase service sales by acquiring treatment service locations in the U.S.
2,374

(Millions of yen)

Services

1,347
204

85（+383%）

140

Sales

140+54M（+63%）

85

1,057+782M

986

1,248

Rental+190M（+18%）

Income from treatment services of RISE Group in theU.S., etc. +750M

Sales revenue from sales of products for research suchas Acoustic X**Acoustic X：Photoacoustic Imaging device using LED Light array

Increase of HAL rented outside Japan +181M

Service: Revenue from service at a point of time
Sales: Revenue from sales at a point of time

FY2021 Q1-Q3 FY2022 Q1-Q3

Rental and maintenance: revenue over time7

Number of operating units
Growth of Medical Lower Limb Type (overseas) and Single Joint Type (domestic) rentals(Unit: Millions of yen)
Product classification

FY2021Q3

HAL Lower Limb Type(Medical)

413

505 *１40%

HAL Lower Limb Type(Non-medical)

141

131

10%

HAL Single Joint Type92135 *２

11%

Care support
and well-being

HAL Lumbar Type194

17814%

Labor Support

HAL Lumbar Type78514%

Cleaning/disinfection/transportation robot

39373%

Other

100

21017%

Total

1,057

1,248

100%

For Hospitals(improving function)

FY2022
Q3(Ratio)*１ HAL Lower Limb Type (Medical)
The main factors of the increase in sales
were from APAC and Europe*２ HAL Single Joint TypeThe main factors of the increase in sales
were Japanese hospitals

9連結売上実績 (地域別)Siginificant increase of oversea sale +946M (22% to 52% of total revenue)

Americas 1%
EMEA 10%APAC 11%• Significant increase in revenue due to the acquisition of treatment sites in the U.S.
• APAC increased sales by 78% and EMEA increased sales by 43%

¥14M
¥136M
¥145M

Americas 33%¥790M

JapanJapan78%(¥1,053M)

FY2021 Q1-Q3
Americas: North, Central and South America
EMEA : Europe, the Middle East and Africa
APAC : Asia-Pacific * Revenue from Japan is stated separately

EMEA 8%APAC 11%

48%

¥193M

(¥1,133M)¥257M

FY2022 Q1-Q311Ref) by geographical regions and type of transaction
Significant revenue growth in U.S. services and rentals in EMEA and APAC
FY2022 Q1-Q3(FY2021 Q1-Q3)

JapanAmericas(Unit : Millions of yen)

RentalSales

ServiceTotal

835

114

185

1,133(824)

(76)

(154)

(1,053)

23

17750

790

(14)

(0)

(0)

(14)

EMEA

144

050

193

(77)

(9)

(50)

(136)

APAC

246

10

1257(143)

(1)

(0)

(145)

1,248

140

987

2,374

(1,057)

(85)

(204)

(1,348)Total

13

Development pipeline
Target disease

ProductDevelopment

Clinical Trial(Exploratory)

Clinical Trial(Validation)

Application/examination

Approval

Marketing(public healthinsurance in Japan)(Post-marketingsurveillance)

Public healthinsurance

NeuromuscularDisease(8 types of diseasesuch as ALS)

Spastic paraplegia

PublicHealth
Insurance

Approved(Expanded)(HAM etc.)

Spinal Cord Injury

As of December 31, 2022
Status
Revision of insurance scheme
Public insurance application underreview (Germany)
Planning for public health insurance
Preparing for insurance application
Preparing application for expansion
Preparing application for expansion

Public medical
insurancecoverage forclinical trials

GermanPublic workers
Compensation
insurance

Considering clinical trial
Preparing trial for public healthinsurance (Germany)
Planning for public health insurance
Discussing with the authorities

StrokePlanning for public health insurance
Planning for public health insurance
Investigator-initiated clinical trial

Cerebral Palsy

Multiple Sclerosis
Conducting pilot research
Conducting pilot research

Parkinsons’Disease
The above situation encompasses HAL products (Lower Limb Type and Lumbar Type).
The Single Joint Type has already obtained medical device approval in Japan and the U.S. without limitation on target diseases.

15

Status of approvals by diseases and countries
Significant progress in medical devices in the U.S., Europe, and Asia
【HAL for Medical Use Lower Limb Type】

EMEA

APAC

As of December 31, 2022
StrokeSpinal Cord Injury

Japan(Discussing the result ofthe clinical trial)(HTLV-1-associated myelopathy andhereditary spastic paraplegia are approved)

Approved

USA

Approved

Approved

ApprovedEU

Approved

Approved

Approved

Saudi Arabia

Approved

Approved

Approved

TurkeyApproved

Approved

Approved

Malaysia

Approved

Approved

Approved

Indonesia

Approved

Approved

Approved

ThailandApproved

Approved

Approved

Taiwan(application in progress)

Approved(application in progress)

Singapore

Approved

Approved

Approved

Australia

Approved

Approved

Approved(Planning clinical trial)

Neuromuscular disease**Spinal muscular atrophy, spinal and bulbar muscular atrophy, amyotrophic lateral sclerosis, Charcot-Marie-Tooth disease, distal muscular dystrophy, inclusion body myositis, congenital myopathy, muscular dystrophy

17Oversea expansion of HAL
Progressin US, EU and APAC despite
COVID
HALを使用したNeuroHALFIT®を全国展開（全16箇所）

Yellow indicates new introduction areas after After the outbreak of COVID-19

PolandConstance care

New installation after April 2021

*private insurance
coverageGermany*Covered by Public workers
compensation insurance
and private insurance

EnglandHampshire County Council

Italy
Centro San Girolamo

FranceHospices Civils de Lyon

Spain
BioCruces Bizkaia

Seattle, Washington
SNI Swedish Medical Center
Jacksonville, Florida
Brooks Cybernics Treatment Center

SerbiaTurkeyDiagenics

Switzerland
Saudi Arabia
ALJ HospitalIndia
IBS Hospital

Phillipines
4 facilities in Metropolitan
Area

KuwaitThailandExpands to 3 facilities

TaiwanCHC Group Hospital

California
RISE Physical Therapy(26 facilities)

Singapore General HospitalBrazil

BrazilLarge distribution of HTLV-1associated myelopathy (HAM)
infected individuals

Malaysia
SOCSO Rehab Center
Operated in 10 facilities

Indonesia

Australia
RoboFit

As of December 31, 2022
19

Disclaimer

This presentation contains forward-looking statements concerning
CYBERDYNE, Inc. and its Group’s future plans, strategies and performance.
Forward-looking statements contained in this presentation are based on
information currently available and on certain assumption redeemed rational at
the time of creation of this presentation. As such, due to various risks anduncertainties, the statements and assumption does not guarantee future
performance, may be considered differently from alternative perspectives andmay differ from the actual result.
Further, this presentation contains statements and information regarding
corporate entities other than those belonging to the CYBERDYNE group, whichhave been complied from various publicly- available sources. CYBERDYNE
does not verify nor guarantees accuracy and appropriateness of thoseinformation.

20